Deepak Bhatt, MD: Icosapent Ethyl Use in Patients with Prior Myocardial Infarction
Dr. Bhatt discusses a subgroup analysis of the REDUCE-IT to determine if icosapent ethyl reduced further ischemic events in patients with prior MI.
Salt Substitute Reduces Risks of Cardiovascular Events
Investigators find that substitute salt better protects older people with a history of stroke or high blood pressure against secondary outcomes of cardiovascular events and death.
Immediate Angiography Not Preferred Over Delayed or Selective Strategies
A recent study found no benefits of immediate angiography over a delayed or selective strategy with respect to the 30-day risk of death from any cause.
Finerenone Improves CV Outcomes in Patients with T2D, CKD in FIGARO-DKD Study
Incidence of death from cardiovascular causes was lower in the finerenone group (458 of 3686 patients) compared to the placebo group (519 of 3666 patients).
Single Month of Dual Antiplatelet Therapy Noninferior to Continued Therapy After PCI
Net adverse clinical events occurred in 165 patients in the abbreviated-therapy group and 172 in the standard therapy group in patients at high bleeding risk after PCI.
Edoxaban Non-Inferior to Vitamin K Antagonist for Post-TAVR Atrial Fibrillation
The direct-acting oral anticoagulant benefitted prevention of adverse clinical events, but was associated with worse major bleeding.
Empagliflozin Reduces Hospitalizations, Deaths in HFpEF Patients
New EMPEROR-Preserved findings show the SGLT-2 inhibitor significantly reduced heart failure-related hospitalizations, regardless of patient diabetes status.
New Targeted Inhibitor Offers Promise for Patients with Symptomatic Obstructive HCM
Current therapies focus on relief of symptoms, but there is still an unmet need to address and target the molecular defects of hypertrophic cardiomyopathy.
The COVID-19 and Cardiovascular Risk Intersection: 3 Major Considerations
Manan Pareek, MD, PhD gives an overview about what is currently known about COVID-19 and cardiovascular risk.
Empagliflozin Improves CV Outcomes in Patients with Obstructive Sleep Apnea
Investigators report on a post-hoc analysis of the EMPA-REG OUTCOME trial that assesses the efficacy of the SGLT-2 inhibitor in patients with obstructive sleep apnea.
Evolocumab Helps Type 2 Diabetes Patients Reach Lipid Level Goals
These guidelines set by ESC and EAS 2019 established treatment goals for LDL-C, non-HDL-C, and Apo-B in patients at high risk for cardiovascular disease.
New Lifetime Risk Equation More Accurately Predicts CV Risk and Treatment Benefits
The new equation model has shown to be more accurate than the Framingham Lifetime Risk equation and Pooled Cohort Equation.
HDL-C Not Determinant in Improved CAD Treatment
Post hoc analysis of REAL-CAD shows the cholesterol metric does not serve to inform statin treatment control of coronary artery disease.
ESC 2020 Takeaways
The congress president shares her favorite sessions, and ideas to integrate virtual setting successes into next year's meeting.
BMI Strongly Predicts Individual Risk for Diabetes
New data shows that high BMI individuals who were in the lowest polygenic score quintile had a 5-fold greater risk of diabetes than those with low BMI and a high polygenic score.
Premenopausal Women Demonstrate Better Long-Term Heart Attack Outcomes
According to late breaking data, younger women exhibit a decreased risk for heart attack mortality due to estrogen’s protective effect
Keeping Virtual Features in Future Cardiology Meetings
What ESC has learned about the benefits and difficulties of online-only forums.
PCSK9 Inhibitors for Familial Hypercholesterolemia Not Dependent on Gene Mutation
Evolocumab and alirocumab produced LDL-C reduction in patients regardless of underlying mutations, investigators reported.
Noise, Air Pollution Impact Cardiovascular Health
This underscores a need to reinvent cities and address environmental risk factors that are associated with increased risk for cardiovascular diseases.
Apple Smart Watch ECG Provides ST-Elevation Reading Accuracy
Myocardial infarction patients were provided ECG readings as reliable as those provided by standard devices.
Climate Change Linked to Cardiovascular Risk Increase
Studies have shown that heat-related cardiovascular events have increased over recent years.
COVID-19 Associated with High Prevalence of CV Risk Factors, Mortality
New cohort data shows that at least 40% of COVID-19 positive patients had CV risk factors, such as diabetes and hypertension.
SGLT2 Inhibitors Emerge As Treatment Options for Heart Failure Patients
Dapagliflozin and empagliflozin are shown to minimize CV events in patients with heart failure and a reduced ejection fraction.
How the ESC 2020 Congress Went Virtual
A look at how a major international cardiovascular meeting changed its structure in 4 months.
How the Microbiome Influences Cardiovascular Disease
A look at how different organisms are influenced differently by harmful foods or common therapies linked to cardiovascular risks.
Clinical, Psychological Factors Similar Between SAMS and non-SAMS Patients
Investigators did note that belief in statin use was weaker in patients with confirmed statin associated muscle symptoms when compared with non-SAMS patients.
Physical Fitness Significantly Influences Obese Women's Cardiovascular Risk
New findings suggest the "obesity paradox" may be explained by rates of exercise among women.
Accurate CV Lifetime Risk Calculators Need Further Development
Accurately assessing lifetime risk in patients with developing atherosclerosis may help reduce CV disease risk earlier in life.
Bempedoic Acid Extension Study Demonstrates Durable Lipid Lowering
The CLEAR Harmony open-label extension study reports on the long-term effects of BA treatment for hypercholesterolemia.
Evolocumab Drops Pediatric Familial Hypercholesterolemia LDL-C by 44%
The new findings break ground on placebo-controlled assessment of the PCSK9 inhibitor for the pediatric population.
